GNAO1 and Encephalopathy: Following our recent example of such an approach dedicated to another rare disease—the GNAO1 encephalopathy [19,20,25]—we built a high-throughput screening (HTS) pipeline using our in vitro BRET assay to look for a repositioning small molecule drug candidate that could modulate the interaction between mutant 14-3-3γ and a phosphopeptide (Figure 3A).